Tag Archives | genomics personalized medicine

2019 J.P.Morgan Healthcare Notes #1 Panel: Reinventing the Disease Continuum Through Precision Health…Update

click here for more Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from  BIO 2016. There are over 70 genes that need to be tested and voluminous data is being generated […]

Continue Reading 0

Big Biopharma Bounce off Bottom: Mid Caps…Updates

http://liberationiraq.com/2016/05/irak-un-schindler-juif-a-deja-sauve-plus-de-120-fillettes-chretiennes-infocom-net/?share=facebook 1/7/19 …After Close: Most Mid-Caps held gains but check AH trading Selected Winners today: AGIO 8.7%, ALNY 8.75%, ARRY 8.85%, BLUE 6.67%, BPMC 14.1%, NKTR 7.83%, SGEN 5.68%, ICPT 7.28%, XBI 5.97% (closed at highs. $79.50). Many of these mid-caps are still at low end of 52 week range. Selected stocks above 52 week mid-range: […]

Continue Reading 0

Free Falling Biotech Stocks Hit New 52 Week Lows…Updates 12/29

directory Update: 12/29/18 Biotech Stocks Halt Slide: IBB down 0.34% to $94.84 and up 4.7% for the week, XBI up 0.73% to $70.09 and up 5.6% for the week. XLV up 3.5% for the week to $85.25.Volatile market trying to hold DEC 24 bottom. Recent trades that worked: ABBV AMGN ; did not work ALXN CELG […]

Continue Reading 0

Trade Fears Derail Biotech Rally in a Jittery Market…Updates

Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down 19.13% to $18.60: Largest Biotech to Go Public…https://finance.yahoo.com/news/nasdaq-welcomes-moderna-inc-nasdaq-185435974.html ======= Update-3 After […]

Continue Reading 0

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno Biopharma Portfolio Movers: AMGN TSRO…Updates

9/16 The Week That Was: September Trending Down for Biotech NASDAQ-100 Holding (QQQ) at 184 up 1.7% last week. Large caps all weak on Friday; key will be Q3 earnings. FBT, IBB and XBI flat for the week; off highs reached 8/31/18. Mid-caps more mixed with strength in ICPT LGND NBIX NVCR RARE SGEN Healthcare […]

Continue Reading 0

Biotechs Surge in August Best in Years: New Highs Hit for 2018…Updates

9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down 3.55%, BIIB down 3.06%, ALXN down 2.66%, GILD down 2.55%, […]

Continue Reading 0

Biotech Snapshot: Healthcare Sector Remains Strong-Updates

8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500, Russell 2000, NASDAQ Composite IBB at $117.40 pushing toward 2018 FEB […]

Continue Reading 0

Rayno Biopharma Portfolio 2018 YTD: Performance Summary

9/10 Update: Long Tesaro (TSRO) We added small positions at $32 on August 21 and more on 9/7 at $35+. =============== Rayno Biopharma Performance 2018: YTD 8/4 Large Caps Begin to Outperform FBT Is the Best All Around Life Science Play up 19% YTD We have provided herein a summary of biopharma portfolio positions for […]

Continue Reading 0